A Phase 4 interventional study of Instillation of Bupivacaine with epinephrine over the diaphragm in Postoperative Pain and Shoulder Pain, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Cedars-Sinai Medical Center · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pain, Postoperative by Cedars-Sinai Medical Center — 3 open to participants now, 3 under way, none of them phase 3. Pain, Postoperative · Cedars-Sinai Medical Center.
Among the 15 studies in Pain, Postoperative by Cedars-Sinai Medical Center, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 4, and was the 15th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →3 of the 15 studies in Pain, Postoperative by Cedars-Sinai Medical Center are open now, in 1 country. Recruiting first, the newest first:
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 80 across the 12 interventional studies, 40 across the 3 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
2 of the studies in Pain, Postoperative by Cedars-Sinai Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400146Cedars-Sinai Medical CenterBupivacaine With Epinephrine Over Diaphragm in Laparoscopy | 2027-01 |
| NCT06338865Cedars-Sinai Medical CenterShort Title: Standard vs. Lower Pressure Pneumoperitoneum | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Pain, Postoperative by Cedars-Sinai Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative shoulder pain is often reported to be particularly bothersome after laparoscopy. The benefits of local anesthetic, such as bupivacaine, applied to subcutaneous tissue for general postoperative pain management after surgery is well established. However, there have been no studies on sprayed bupivacaine over the diaphragm to reduce shoulder pain in laparoscopic surgery. The purpose of the study is to evaluate if sprayed infra-diaphragmatic bupivacaine compared to placebo (saline) will improve postoperative shoulder pain in patients undergoing benign laparoscopic gynecologic surgery. The entire study will be conducted at Cedar Sinai Medical Center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will have 30 mL of 0.25% bupivacaine with epinephrine 1:200,000 (total of 75 mg) placed over the diaphragm laparoscopically at the conclusion of the laparoscopic gynecologic procedure.
Drug: Instillation of Bupivacaine with epinephrine over the diaphragm
No additional intervention will be performed.
Prior to desufflation of the abdomen during the laparoscopic gynecologic procedure, the surgeon will instill 30mL of 0.25% bupivacaine with epinephrine 1:200,000 (total of 75 mg) laparoscopically aiming to cover the diaphragm with liquid.
Post-operative shoulder pain scores
Reported right shoulder pain score using visual analog score (VAS) 24 hours postoperatively Null hypothesis = pain scores will not differ among the bupivacaine with epinephrine vs no intervention group Alternative hypothesis = pain scores will be lower among the bupivacaine with epinephrine group Assessed using the validated 100-mm scale with a range of 0-10 (11-point numerical rating scale), an ordinal scale Analyzed using the Kruskall Wallis test (as the data from the scale is typically not normally distributed); pairwise analyses will then be conducted using the Dunn post-hoc test if statistically significant Assuming non-normality, data will be presented as median (range) Patients without any postoperative documentation of pain scores will be withdrawn from the study and thus excluded from the analysis
Time frame: 24 hours postoperatively
Post-operative generalized pain scores
Post-operative generalized pain scores (superiority): Null hypothesis = pain scores will not differ among the bupivacaine with epinephrine vs no intervention group Alternative hypothesis= pain scores will be lower among the bupivacaine with epinephrine group First and last reported generalized pain score in post-anaesthesia care unit (PACU) using numerical rating score Assessed using the validated 11-point numerical rating scale (0-10), an ordinal scale Analyzed using the Kruskall Wallis test (as the data from the scale is typically not normally distributed); pairwise analyses will then be conducted using the Dunn post-hoc test if statistically significant Assuming non-normality, data will be presented as median (range) Patients without any postoperative documentation of pain scores will be withdrawn from the study and thus excluded from the analysis
Time frame: up to 6 hours in post-anaesthesia care unit (PACU)
Total analgesic requirements in post-anaesthesia care unit (PACU) in morphine equivalents
Calculated in morphine milligram equivalents (continuous data) Analyzed using the Kruskall-Wallis test (assuming non-normal data) Data will be presented as median (range)
Time frame: up to 6 hours in post-anaesthesia care unit (PACU)
Length of stay in post-anaesthesia care unit (PACU)
Length of stay in post-anaesthesia care unit (PACU) (superiority): Null hypothesis = PACU length of stay will not differ among the bupivacaine with epinephrine vs no intervention group Alternative hypothesis= PACU length of stay will be shorter in the bupivacaine with epinephrine groups Documented in minutes (continuous data) Analyzed using ANOVA if normally distributed, Kruskall-Wallis test if not normally distributed
Time frame: up to 6 hours in post-anaesthesia care unit (PACU)
Post-operative shoulder pain scores at home
Daily reported post-operative shoulder pain scores at home (superiority): Null hypothesis = pain scores will not differ among the bupivacaine with epinephrine vs no intervention group Alternative hypothesis = pain scores will be lower among the bupivacaine with epinephrine group Assessed using the validated 100-mm scale with a range of 0-10 (11-point numerical rating scale), an ordinal scale Analyzed using the Kruskall Wallis test (as the data from the scale is typically not normally distributed); pairwise analyses will then be conducted using the Dunn post-hoc test if statistically significant Assuming non-normality, data will be presented as median (range) Patients without any postoperative documentation of pain scores will be withdrawn from the study and thus excluded from the analysis
Time frame: 7 days postoperatively
Post-operative opioid use
Post-operative opioid use (superiority): Null hypothesis = post-op opioid use will not differ among the bupivacaine with epinephrine vs no intervention group Alternative hypothesis= post-op opioid use will be lower among the bupivacaine with epinephrine group Number of pills used reported by patient (interval data) Analyzed using the Kruskall-Wallis test Data will be presented as median (range)
Time frame: 1 week postoperative
Surgical outcome: EBL
Surgical outcomes: EBL (mL) Null hypothesis = outcome will not differ between groups Alternative hypothesis = outcome will be improved in bupivacaine with epinephrine group Continuous variables: estimated blood loss Analyzed using ANOVA if normally distributed, Kruskall-Wallis test if not normally distributed
Time frame: up to 8 hours
Surgical outcome: operative time
Surgical outcomes: operative time (minutes) Null hypothesis = outcome will not differ between groups Alternative hypothesis = outcome will be improved in bupivacaine with epinephrine group Continuous variables: operative time, estimated blood loss Analyzed using ANOVA if normally distributed, Kruskall-Wallis test if not normally distributed
Time frame: up to 8 hours
Surgical outcome: intraoperative complications
Surgical outcomes: intraoperative complications Null hypothesis = outcome will not differ between groups Alternative hypothesis = outcome will be improved in bupivacaine with epinephrine group Binary data: Surgical complications (yes/no) Analyzed using chi-square test
Time frame: within 1 week of surgery
Surgical outcomes: conversion to laparotomy
Surgical outcomes: conversion to laparotomy Null hypothesis = outcome will not differ between groups Alternative hypothesis = outcome will be improved in bupivacaine with epinephrine group Binary data: conversion to laparotomy (yes/no) Analyzed using chi-square test
Time frame: within 6 hours of surgery start time
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Jan 2027, 10 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 10 months is below that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Feb 2026 → Mar 2026, primary completion Jul 2026 → Jan 2027 and completion Aug 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.